Rejuvenate Bio, Inc.
Raising nowOperatingRejuvenate Bio Inc
Biotech · San Diego, CA
Reversing age-related decline — proven in animals, advancing to humans
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Cap table
Principal holders% as the filing states it, Apr 28, 2026
- Noah DavidsonCommon Stock49.0%of
- Daniel OliverCommon Stock33.0%of
Sold to the crowd
- Reg CF · Apr 20263,366,505 Equity at $0.91$3.1M· 1,215 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
11 people
Biotech entrepreneur. 3x founder. Secured agreements representing $130M+ in potential value. Former founder of Voxel8, Wyss Institute spinout; $14M raised prior to acquisition by Kornit. Caltech Mechanical Engineering & Business BS, Harvard MBA.
Synthetic biology pioneer. Invented genetic reprogramming technologies that extend lifespan. Author of 17 scientific papers with 128 influential citations. Harvard Medical School postdoctoral fellow. Caltech BS, Princeton MS, MIT PhD.
Award-winning geneticist and TIME 100 awardee. Co-founded nearly 50 biotechs (9 exits) including Editas Medicine (NASDAQ: EDIT). Harvard Medical School professor and early CRISPR pioneer. Duke BS, Harvard Biochemistry and Molecular Biology PhD.
Testing expert. 20+ years building in vitro and in vivo AAV assays across academia and biotech. Leads FDA-ready potency, tox and bioanalytical assay development, pIND packages and AAV platform optimization for gene therapy drug candidates.
Veterinary R&D expert. Former head of R&D at Merial, Novartis Animal Health and Boehringer-Ingelheim, leading vaccine, biologics and therapeutics portfolios. Led ILRI’s livestock health agenda in Africa and Asia and chaired PetMedix through its 2023 exit.
Regulatory strategist. 20+ years shaping gene therapy, biologics and small molecule programs across FDA, startups and consulting. Designs global CMC, nonclinical and clinical strategies that unlock approvals for complex advanced therapies.
Manufacturing strategist. Former Merck senior leader managing $100M+ global sites; ex-VP Manufacturing at Spark Therapeutics. Founder of SMART Bio Works, optimizing cGMP facilities and high-performing CMC teams.
Scaling operator. 30+ years leading R&D across infectious disease, oncology, neurology, ophthalmology, and cardiovascular. From Pfizer and Amgen to nine biotech startups. Led programs through FDA approval applications and product launches.
Operational Strategist. Principal consultant with 25+ years in regenerative medicine and cold chain; ex-director at Harvard Apparatus Regenerative Technology and Cold Chain Technologies. Designs data-driven processes that de-risk commercialization.
Show 2 more peopleShow fewer
Gene carrier pioneer. Former Merck VP leading vaccine and biologics bioprocess R&D; ex-process and manufacturing chief at Genovo and Targeted Genetics. Now advisor on virology, vectors and GMP manufacturing and founder of RWP BioConsulting.
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.